Advanced search
Publication Cover
Future Science OA Volume 10, 2024 - Issue 1
Submit an article Journal homepage
289
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Clinical approach and utilizing liquid biopsies to interrogate suspected acquired resistance to PD-1 blockade

Dilanka Lakshan De Silva1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;2 Parkville Familial Cancer Centre, Peter MacCallum Centre, Melbourne, Victoria, 3000, Australia;3 Peter MacCallum Department of Oncology, University of Melbourne Victoria, 3010, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7937-2541
ORCID Icon &
Jia Luo1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;4 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;5 Department of Medicine, Harvard Medical School, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0003-3606-827X
ORCID Icon
Article: FSO937 | Received 24 Jan 2023, Accepted 07 Nov 2023, Published online: 31 Jan 2024

References

  • Brahmer JR, Govindan R, Anders RA et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J. Immunother. Cancer 6(1), 75 (2018).
  • Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168(4), 707–723 (2017).
  • Kluger HM, Tawbi HA, Ascierto ML et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J. Immunother. Cancer 8(1), 398 (2020).
  • Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell 37(4), 443–455 (2020).
  • Cheng DT, Mitchell TN, Zehir A et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J. Mol. Diagn. 17(3), 251–264 (2015).
  • Rose Brannon A, Jayakumaran G, Diosdado M et al. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nat. Commun. 12(1), 3770 (2021).
  • Shah S, Wood K, Labadie B et al. Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. Oncotarget 9(4), 4375–4384 (2018).
  • Huo YR, Chan MV, Habib AR, Lui I, Ridley L. Pneumothorax rates in CT-Guided lung biopsies: a comprehensive systematic review and meta-analysis of risk factors. Br. J. Radiol. 93(1108), 20190866 (2020).
  • Boskovic T, Stanic J, Pena-Karan S et al. Pneumothorax after transthoracic needle biopsy of lung lesions under CT guidance. J. Thorac. Dis. 6(Suppl. 1), S99–S107 (2014).
  • Song Y, Hu C, Xie Z et al. Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Transl. Lung Cancer Res. 9(2), 269–279 (2020).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.